Versor Investments LP Raises Position in IQVIA Holdings Inc. $IQV

Versor Investments LP increased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 94.1% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,398 shares of the medical research company’s stock after buying an additional 3,102 shares during the period. Versor Investments LP’s holdings in IQVIA were worth $1,008,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Clal Insurance Enterprises Holdings Ltd raised its position in IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 131 shares in the last quarter. AllSquare Wealth Management LLC purchased a new stake in IQVIA during the first quarter valued at about $33,000. Trust Co. of Toledo NA OH purchased a new stake in IQVIA during the second quarter valued at about $39,000. J.Safra Asset Management Corp raised its position in IQVIA by 208.6% during the second quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 169 shares in the last quarter. Finally, Larson Financial Group LLC raised its position in IQVIA by 109.9% during the first quarter. Larson Financial Group LLC now owns 275 shares of the medical research company’s stock valued at $48,000 after purchasing an additional 144 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the transaction, the insider owned 27,108 shares in the company, valued at $5,955,627.60. The trade was a 12.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of research reports. William Blair restated an “outperform” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Robert W. Baird set a $258.00 price target on IQVIA and gave the company an “outperform” rating in a research report on Wednesday. HSBC upgraded IQVIA from a “hold” rating to a “buy” rating and raised their price target for the company from $195.00 to $235.00 in a research report on Thursday, October 9th. Evercore ISI raised their price objective on IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a research note on Wednesday, October 8th. Finally, Baird R W raised IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 29th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $241.41.

IQVIA Stock Down 0.0%

Shares of NYSE:IQV opened at $216.43 on Monday. The stock’s 50-day moving average price is $197.12 and its 200-day moving average price is $174.12. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $225.91. The stock has a market capitalization of $36.86 billion, a P/E ratio of 29.69, a price-to-earnings-growth ratio of 2.42 and a beta of 1.34. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The company had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $4.07 billion. During the same quarter in the previous year, the business earned $2.84 EPS. IQVIA’s revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.